Skip to content

Clinical Study of HRS-2129 for Postoperative Analgesia in Orthopaedics

Clinical Study on Safety and Efficacy of HRS-2129 for Postoperative Analgesiain Orthopaedics

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06780267
Enrollment
199
Registered
2025-01-17
Start date
2025-03-11
Completion date
2026-04-03
Last updated
2026-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain in Orthopaedics

Brief summary

The study is being conducted to evaluate the safety, and efficacy of HRS-2129 for Postoperative analgesia in orthopaedics. To explore the reasonable dosage of HRS-2129 for Postoperative analgesia in orthopaedics.

Interventions

HRS-2129

HRS-2129 placebo

Tramadol Hydrochloride SR Tablets

Sponsors

Shandong Suncadia Medicine Co., Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Able and willing to provide a written informed consent 2. Subjects requiring elective orthopedic surgery 3. Conform to the ASA Physical Status Classification

Exclusion criteria

1. Subjects with a history of severe allergies 2. Subjects with nervous system disease 3. Subjects with a history of mental illness 4. Subjects with abnormal liver and renal function 5. Subjects with poorly controlled hypertensive or hypotensive 6. QTc:\>450ms(male),\>470ms(female) 7. Subjects who screened positive for substance abuse 8. History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s) 9. The investigators determined that other conditions were inappropriate for participation in this clinical trial

Design outcomes

Primary

MeasureTime frame
Safety:Incidence and severity of AE/SAEfrom ICF signing date to day 12 since last dose(14 days)

Secondary

MeasureTime frame
the Sum of Pain Intensity Differences in Pain Score Over 6hour、12hour、16hour、24hour、48hour、12hour-24hour、24hour-48hour under static and moving condition48hours
The response rate of NRS scores under static and moving condition at 24hour and 48hour after the first dose of medication48hours
Participant ' satisfaction score for analgesia treatment48hours
Investigator satisfaction score for analgesia treatment48hours
Time of first use of remedial analgesic medication48hours
Cumulative use of remedial analgesics48hours
Cmax5 days
Tmax5 days
AUC0-12h5 days

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 3, 2026